<DOC>
	<DOCNO>NCT00000838</DOCNO>
	<brief_summary>To evaluate efficacy , safety , pharmacokinetics lamivudine ( 3TC ) combine zidovudine ( AZT ) , stavudine ( d4T ) , didanosine ( ddI ) comparison d4T ddI monotherapy HIV-infected patient prior nucleoside therapy . 3TC may uniquely effective combination AZT due interaction AZT 3TC resistance mutation . One explanation M184V mutation , confers resistance 3TC , suppress AZT resistance . This benefit 3TC may extend combination therapy nucleoside analog .</brief_summary>
	<brief_title>Antiviral Activity Resistance Lamivudine Combination With Zidovudine , Stavudine , Didanosine</brief_title>
	<detailed_description>3TC may uniquely effective combination AZT due interaction AZT 3TC resistance mutation . One explanation M184V mutation , confers resistance 3TC , suppress AZT resistance . This benefit 3TC may extend combination therapy nucleoside analog . Patients randomize either ddI limb d4T limb , randomize second time one six treatment arm , follow : ddI alone , d4T alone , 3TC/AZT ( ddI d4T limb ) , 3TC/ddI , 3TC/d4T . Treatment give 48 week . At study week 24 , patient monotherapy 3TC added regimen ( blinded fashion ) . PER AMENDMENT 10/18/96 : A treatment extension phase add study design order allow subject complete 48 week therapy remain blinded treatment approximately 2 month last enrol subject completes 48 week study .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : PCP prophylaxis . Patients must : HIV infection . CD4 count 200 600 cells/mm3 . Life expectancy least 24 week . Consent parent guardian le 18 year old . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Unexplained temperature &gt; = 38.5 C 7 consecutive day within 30 day prior study entry . PER AMENDMENT 1/25/96 : A malignancy require systemic chemotherapy Kaposi 's sarcoma . Concurrent Medication : Excluded : Concurrent antiretroviral immunologic agent . Other experimental therapy . Systemic corticosteroid ( except adjuvant therapy acute PCP ) immunosuppressive drug . Systemic cytotoxic chemotherapy . Induction maintenance foscarnet ganciclovir ( oral IV ) . Patients follow prior condition exclude : History acute chronic pancreatitis . History grade 2 high peripheral neuropathy . Prior Medication : Excluded : Antiretrovirals within 90 day prior study entry . More 7 day total lifetime use antiretroviral nucleoside .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Stavudine</keyword>
	<keyword>Lamivudine</keyword>
</DOC>